KR20200070416A - Tor 키나제 억제자를 사용하는 암의 치료 - Google Patents

Tor 키나제 억제자를 사용하는 암의 치료 Download PDF

Info

Publication number
KR20200070416A
KR20200070416A KR1020207016306A KR20207016306A KR20200070416A KR 20200070416 A KR20200070416 A KR 20200070416A KR 1020207016306 A KR1020207016306 A KR 1020207016306A KR 20207016306 A KR20207016306 A KR 20207016306A KR 20200070416 A KR20200070416 A KR 20200070416A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
pyrazin
tor kinase
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207016306A
Other languages
English (en)
Korean (ko)
Inventor
슈이찬 주
크리스튼 메이 헤게
헤더 레이몬
릴리 로레인 웡
Original Assignee
시그날 파마소티칼 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 엘엘씨 filed Critical 시그날 파마소티칼 엘엘씨
Priority to KR1020217017407A priority Critical patent/KR20210071101A/ko
Publication of KR20200070416A publication Critical patent/KR20200070416A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207016306A 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료 Ceased KR20200070416A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217017407A KR20210071101A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US61/611,361 2012-03-15
US201261715323P 2012-10-18 2012-10-18
US61/715,323 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147028707A Division KR102122617B1 (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217017407A Division KR20210071101A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Publications (1)

Publication Number Publication Date
KR20200070416A true KR20200070416A (ko) 2020-06-17

Family

ID=48014336

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207016306A Ceased KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020217017407A Ceased KR20210071101A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020147028707A Active KR102122617B1 (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217017407A Ceased KR20210071101A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020147028707A Active KR102122617B1 (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Country Status (21)

Country Link
US (1) US20130245026A1 (https=)
EP (1) EP2825170B1 (https=)
JP (3) JP2015510891A (https=)
KR (3) KR20200070416A (https=)
CN (2) CN104519885A (https=)
AU (1) AU2013203153B2 (https=)
BR (1) BR112014022703A2 (https=)
CA (1) CA2866872A1 (https=)
EA (1) EA028414B1 (https=)
ES (1) ES2677874T3 (https=)
IL (1) IL234602B (https=)
MX (1) MX360878B (https=)
MY (1) MY174022A (https=)
NI (1) NI201400111A (https=)
NZ (1) NZ628416A (https=)
PH (1) PH12014502029B1 (https=)
SG (1) SG11201405707XA (https=)
TW (1) TWI583385B (https=)
UA (1) UA114315C2 (https=)
WO (1) WO2013138557A1 (https=)
ZA (1) ZA201406706B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022703A2 (pt) * 2012-03-15 2021-05-04 Signal Pharmaceuticals, Llc método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
TW201526894A (zh) * 2013-04-17 2015-07-16 Signal Pharm Llc 藉二氫吡并吡治療癌症
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
SG10201500511TA (en) 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
BR112014022703A2 (pt) * 2012-03-15 2021-05-04 Signal Pharmaceuticals, Llc método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit

Also Published As

Publication number Publication date
UA114315C2 (uk) 2017-05-25
KR102122617B1 (ko) 2020-06-12
CN104519885A (zh) 2015-04-15
CA2866872A1 (en) 2013-09-19
BR112014022703A2 (pt) 2021-05-04
IL234602A0 (en) 2014-11-30
JP2015510891A (ja) 2015-04-13
WO2013138557A1 (en) 2013-09-19
MY174022A (en) 2020-03-04
KR20140138927A (ko) 2014-12-04
KR20210071101A (ko) 2021-06-15
SG11201405707XA (en) 2014-10-30
EP2825170A1 (en) 2015-01-21
PH12014502029A1 (en) 2014-11-24
ES2677874T3 (es) 2018-08-07
JP2021102637A (ja) 2021-07-15
NZ628416A (en) 2016-04-29
ZA201406706B (en) 2016-05-25
US20130245026A1 (en) 2013-09-19
TWI583385B (zh) 2017-05-21
EA028414B1 (ru) 2017-11-30
JP2019108368A (ja) 2019-07-04
MX360878B (es) 2018-11-21
EA201491699A1 (ru) 2015-02-27
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
HK1201750A1 (en) 2015-09-11
MX2014011077A (es) 2014-10-14
NI201400111A (es) 2015-01-15
EP2825170B1 (en) 2018-05-09
AU2013203153B2 (en) 2015-09-03
IL234602B (en) 2020-05-31
CN108992446A (zh) 2018-12-14
TW201343168A (zh) 2013-11-01

Similar Documents

Publication Publication Date Title
KR102122617B1 (ko) Tor 키나제 억제자를 사용하는 암의 치료
US20230338370A1 (en) Treatment of Cancer with TOR Kinase Inhibitors
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
EP2825168B1 (en) Treatment of cancer with tor kinase inhibitors
JP2016516671A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの治療
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors
AU2015201138A1 (en) Treatment of cancer with TOR kinase inhibitors
AU2015213400A1 (en) Treatment of cancer with TOR kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200605

Application number text: 1020147028707

Filing date: 20141014

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200728

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210127

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200728

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210127

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200925

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210406

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210302

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210127

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200925

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200728

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210607

Application number text: 1020147028707

Filing date: 20141014

PJ0201 Trial against decision of rejection

Patent event date: 20210607

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20210406

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20210127

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20220331

Appeal identifier: 2021101001442

Request date: 20210607

J301 Trial decision

Free format text: TRIAL NUMBER: 2021101001442; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20210607

Effective date: 20220331

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20220331

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20210607

Decision date: 20220331

Appeal identifier: 2021101001442

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220412

Patent event code: PE09021S01D

PS0601 Decision to reject again after remand of revocation

Patent event date: 20221017

Comment text: Decision to Refuse Application

Patent event code: PS06013S01D

Patent event date: 20220412

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

Patent event date: 20220404

Comment text: Notice of Trial Decision (Remand of Revocation)

Patent event code: PS06011S01I

Patent event date: 20200728

Comment text: Notification of reason for refusal

Patent event code: PS06012S01I

S601 Decision to reject again after remand of revocation